Carregant...

Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy

Latanoprostene bunod (LBN) 0.024%, a modified prostaglandin analog, was approved on November 2, 2017, for the reduction of IOP in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). LBN works by combining the IOP-lowering effects of the prostaglandin analogs (through the uveosclera...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Ophthalmol
Autors principals: Addis, Victoria M, Miller-Ellis, Eydie
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2018
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6304237/
https://ncbi.nlm.nih.gov/pubmed/30587912
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OPTH.S156038
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!